88 related articles for article (PubMed ID: 19576120)
1. [A comparison of efficacy and tolerance of nateglinide and acarbose monotherapy in type 2 diabetes mellitus].
Pan CY; Gao Y; Li GW; Zhu XX; Gao X; Liu X
Zhonghua Nei Ke Za Zhi; 2009 Apr; 48(4):304-7. PubMed ID: 19576120
[TBL] [Abstract][Full Text] [Related]
2. Differential therapeutic effects of nateglinide and acarbose on fasting and postprandial lipid profiles: a randomized trial.
Zhou J; Deng Z; Lu J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2015 Apr; 17(4):229-34. PubMed ID: 25781235
[TBL] [Abstract][Full Text] [Related]
3. Nateglinide and acarbose are comparably effective reducers of postprandial glycemic excursions in chinese antihyperglycemic agent-naive subjects with type 2 diabetes.
Zhou J; Li H; Zhang X; Peng Y; Mo Y; Bao Y; Jia W
Diabetes Technol Ther; 2013 Jun; 15(6):481-8. PubMed ID: 23631607
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of initial combination therapy with nateglinide and metformin in treatment-naïve patients with type 2 diabetes.
Horton ES; Foley JE; Shen SG; Baron MA
Curr Med Res Opin; 2004 Jun; 20(6):883-9. PubMed ID: 15200747
[TBL] [Abstract][Full Text] [Related]
5. Nateglinide alone and in combination with metformin improves glycemic control by reducing mealtime glucose levels in type 2 diabetes.
Horton ES; Clinkingbeard C; Gatlin M; Foley J; Mallows S; Shen S
Diabetes Care; 2000 Nov; 23(11):1660-5. PubMed ID: 11092289
[TBL] [Abstract][Full Text] [Related]
6. Nateglinide and acarbose for postprandial glucose control after optimizing fasting glucose with insulin glargine in patients with type 2 diabetes.
Kim MK; Suk JH; Kwon MJ; Chung HS; Yoon CS; Jun HJ; Ko JH; Kim TK; Lee SH; Oh MK; Rhee BD; Park JH
Diabetes Res Clin Pract; 2011 Jun; 92(3):322-8. PubMed ID: 21376417
[TBL] [Abstract][Full Text] [Related]
7. Beneficial metabolic effects of nateglinide versus acarbose in patients with newly-diagnosed type 2 diabetes.
Gao HW; Xie C; Wang HN; Lin YJ; Hong TP
Acta Pharmacol Sin; 2007 Apr; 28(4):534-9. PubMed ID: 17376293
[TBL] [Abstract][Full Text] [Related]
8. Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.
Zheng F; Yin X; Lu W; Zhou J; Yuan H; Li H
J Endocrinol Invest; 2013; 36(7):489-96. PubMed ID: 23324437
[TBL] [Abstract][Full Text] [Related]
9. A review of nateglinide in the management of patients with type 2 diabetes.
Tentolouris N; Voulgari C; Katsilambros N
Vasc Health Risk Manag; 2007; 3(6):797-807. PubMed ID: 18200800
[TBL] [Abstract][Full Text] [Related]
10. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients.
Marre M; Van Gaal L; Usadel KH; Ball M; Whatmough I; Guitard C
Diabetes Obes Metab; 2002 May; 4(3):177-86. PubMed ID: 12047396
[TBL] [Abstract][Full Text] [Related]
11. Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84.
Weaver JU; Robertson D; Atkin SL
Diabetes Obes Metab; 2004 Sep; 6(5):344-52. PubMed ID: 15287927
[TBL] [Abstract][Full Text] [Related]
12. [Therapies for newly-onset diabetic patients].
Kawamori R
Nihon Rinsho; 2005 Feb; 63 Suppl 2():525-32. PubMed ID: 15779435
[No Abstract] [Full Text] [Related]
13. Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.
Campbell IW
Int J Clin Pract; 2005 Oct; 59(10):1218-28. PubMed ID: 16178991
[TBL] [Abstract][Full Text] [Related]
14. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone.
Ristic S; Collober-Maugeais C; Pecher E; Cressier F
Diabet Med; 2006 Jul; 23(7):757-62. PubMed ID: 16842480
[TBL] [Abstract][Full Text] [Related]
15. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
[TBL] [Abstract][Full Text] [Related]
16. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
Hanefeld M; Bouter KP; Dickinson S; Guitard C
Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
[TBL] [Abstract][Full Text] [Related]
17. Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia.
Bellomo Damato A; Stefanelli G; Laviola L; Giorgino R; Giorgino F
Diabet Med; 2011 May; 28(5):560-6. PubMed ID: 21204958
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of mitiglinide versus nateglinide in newly diagnose patients with type 2 diabetes mellitus: a randomized double blind trial.
Li L; Yang M; Li Z; Yan X; Guo H; Pan H; Liu H; Liao Y; Yang G
Diabetes Obes Metab; 2012 Feb; 14(2):187-9. PubMed ID: 21895920
[TBL] [Abstract][Full Text] [Related]
19. Nateglinide in combination with metformin in Chinese patients with type 2 diabetes mellitus: a post-marketing surveillance study.
Yang JK; Wang L;
Clin Drug Investig; 2013 Mar; 33(3):185-91. PubMed ID: 23338975
[TBL] [Abstract][Full Text] [Related]
20. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial.
Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
Intern Med; 2007; 46(22):1837-46. PubMed ID: 18025765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]